DJ Slamon

4.3k total citations
80 papers, 2.7k citations indexed

About

DJ Slamon is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Cancer Research. According to data from OpenAlex, DJ Slamon has authored 80 papers receiving a total of 2.7k indexed citations (citations by other indexed papers that have themselves been cited), including 58 papers in Oncology, 36 papers in Pulmonary and Respiratory Medicine and 23 papers in Cancer Research. Recurrent topics in DJ Slamon's work include HER2/EGFR in Cancer Research (38 papers), Advanced Breast Cancer Therapies (33 papers) and Cancer Treatment and Pharmacology (24 papers). DJ Slamon is often cited by papers focused on HER2/EGFR in Cancer Research (38 papers), Advanced Breast Cancer Therapies (33 papers) and Cancer Treatment and Pharmacology (24 papers). DJ Slamon collaborates with scholars based in United States, Germany and Canada. DJ Slamon's co-authors include William Godolphin, Michael F. Press, Giovanni M. Pauletti, Giun‐Yi Hung, M. Pegram, Mark D. Pegram, G. Konecny, John Crown, Tadeusz Pieńkowski and Ravi Patel and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Journal of Clinical Oncology and Blood.

In The Last Decade

DJ Slamon

79 papers receiving 2.6k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
DJ Slamon United States	22	1.9k	1.1k	895	603	546	80	2.7k
Keng‐Hsueh Lan Taiwan	13	1.5k 0.8×	1.5k 1.4×	760 0.8×	325 0.5×	381 0.7×	21	2.5k
Kerstin Borgmann Germany	32	1.2k 0.6×	1.8k 1.7×	504 0.6×	712 1.2×	497 0.9×	85	2.7k
Philippe Aftimos Belgium	25	1.9k 1.0×	934 0.9×	690 0.8×	785 1.3×	809 1.5×	144	3.1k
Amol Tandon United States	11	1.4k 0.7×	887 0.8×	700 0.8×	506 0.8×	199 0.4×	16	2.0k
Tomoyuki Kawamoto Japan	19	1.7k 0.9×	1.5k 1.4×	1.0k 1.1×	267 0.4×	567 1.0×	26	3.0k
Valentina Boni Spain	29	2.3k 1.2×	1.0k 1.0×	771 0.9×	771 1.3×	772 1.4×	189	3.4k
Paula R. Pohlmann United States	22	1.3k 0.7×	655 0.6×	321 0.4×	489 0.8×	535 1.0×	100	2.3k
Lisa Crocker United States	13	2.1k 1.1×	959 0.9×	1.6k 1.8×	205 0.3×	454 0.8×	25	2.7k
S. A. Eccles United Kingdom	22	1.1k 0.6×	807 0.8×	463 0.5×	588 1.0×	305 0.6×	45	2.1k
Sarah Heeson United Kingdom	11	1.5k 0.8×	801 0.8×	607 0.7×	445 0.7×	624 1.1×	23	2.4k

Countries citing papers authored by DJ Slamon

Since Specialization

Citations

This map shows the geographic impact of DJ Slamon's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by DJ Slamon with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites DJ Slamon more than expected).

Fields of papers citing papers by DJ Slamon

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by DJ Slamon. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by DJ Slamon. The network helps show where DJ Slamon may publish in the future.

Co-authorship network of co-authors of DJ Slamon

This figure shows the co-authorship network connecting the top 25 collaborators of DJ Slamon. A scholar is included among the top collaborators of DJ Slamon based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with DJ Slamon. DJ Slamon is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

André, Fabrice, Nadia Solovieff, Fei Su, et al.. (2024). Acquired gene alterations in patients treated with ribociclib plus endocrine therapy or endocrine therapy alone using baseline and end-of-treatment circulating tumor DNA samples in the MONALEESA-2, -3, and -7 trials. Annals of Oncology. 36(1). 54–64. 5 indexed citations

André, Fabrice, Faye Su, Nadia Solovieff, et al.. (2023). Pooled ctDNA analysis of MONALEESA phase III advanced breast cancer trials. Annals of Oncology. 34(11). 1003–1014. 43 indexed citations

Bachelot, Thomas, NU Lin, Sara A. Hurvitz, et al.. (2020). 293P Impact of tucatinib on progression free survival in patients with HER2+ metastatic breast cancer and stable or active brain metastases. Annals of Oncology. 31. S359–S360. 9 indexed citations

Rugo, HS, RS Finn, Véronique Dièras, et al.. (2018). Abstract P5-21-03: Palbociclib (PAL) + letrozole (LET) as first-line therapy in estrogen receptor–positive (ER+)/human epidermal growth factor receptor 2–negative (HER2−) advanced breast cancer (ABC): Efficacy and safety updates with longer follow-up across patient subgroups. Cancer Research. 78(4_Supplement). P5–21. 11 indexed citations

Jiménez, M. Martín, Thomas Bachelot, Carlos H. Barrios, et al.. (2017). EarLEE-1: A phase 3 study of ribociclib + endocrine therapy (ET) for adjuvant treatment of patients (pts) with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2–), high-risk, early breast cancer (EBC). Annals of Oncology. 28. v107–v107. 4 indexed citations

Finn, RS, Yuqiu Jiang, Hope S. Rugo, et al.. (2016). Biomarker analyses from the phase 3 PALOMA-2 trial of palbociclib (P) with letrozole (L) compared with placebo (PLB) plus L in postmenopausal women with ER + /HER2– advanced breast cancer (ABC). Annals of Oncology. 27. vi554–vi554. 46 indexed citations

Rugo, Hope S., Véronique Dièras, Karen A. Gelmon, et al.. (2016). Impact of palbociclib plus letrozole on health related quality of life (HRQOL) compared with letrozole alone in treatment naïve postmenopausal patients with ER+ HER2- metastatic breast cancer (MBC): results from PALOMA-2. Annals of Oncology. 27. vi69–vi69. 6 indexed citations

Finn, Richard S., John Crown, Katalin Boér, et al.. (2012). 100O Results of A Randomized Phase 2 Study of Pd 0332991, A Cyclin-Dependent Kinase (Cdk) 4/6 Inhibitor, In Combination with Letrozole vs Letrozole Alone For First-Line Treatment of ER + /Her2- Advanced Breast Cancer (Bc). Annals of Oncology. 23. ii43–ii43. 30 indexed citations

Bebek, Gürkan, Charles Ginther, Kristen L. Lozada, et al.. (2012). FOXA1 represses the molecular phenotype of basal breast cancer cells. Oncogene. 32(5). 554–563. 116 indexed citations

10.

Lu, Yunfeng, et al.. (2012). Abstract P4-08-05: Basement membrane localized tumor cells are protected from HER2-targeted therapy in vivo.. Cancer Research. 72(24_Supplement). P4–8. 1 indexed citations

11.

Finn, RS, Katalin Boér, Roshni Patel, et al.. (2011). A randomized phase II study of PD 0332991, cyclin-dependent kinase (CDK) 4/6 inhibitor, in combination with letrozole for first-line treatment of patients with postmenopausal, estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer.. Journal of Clinical Oncology. 29(15_suppl). TPS100–TPS100. 4 indexed citations

12.

Konecny, Gottfried E., Rickard Glas, Judy Dering, et al.. (2009). Activity of the multikinase inhibitor dasatinib against ovarian cancer cells. British Journal of Cancer. 101(10). 1699–1708. 81 indexed citations

13.

Chow, Lucy, Charles Ginther, Jane Arboleda, et al.. (2009). The role of receptor tyrosine kinase and activated PI3K signaling in response/resistance to HER-2 targeted therapy.. Cancer Research. 69(2_Supplement). 2013–2013. 1 indexed citations

14.

Pegram, M., Tadeusz Pieńkowski, Donald W. Northfelt, et al.. (2004). Results of Two Open-Label, Multicenter Phase II Studies of Docetaxel, Platinum Salts, and Trastuzumab in HER2-Positive Advanced Breast Cancer. JNCI Journal of the National Cancer Institute. 96(10). 759–769. 202 indexed citations

15.

Konecny, Gottfried E., Jane Arboleda, Carol Wilson, et al.. (2001). Her-2/neu and urokinase-type plasminogen activator and its inhibitor in breast cancer.. PubMed. 7(8). 2448–57. 58 indexed citations

16.

Mass, R., Melody Cobleigh, Charles L. Vogel, & DJ Slamon. (2001). Estrogen receptor status in the Herceptin (trastuzumab) clinical trials: Incidence and relation to clinical benefit. Breast Cancer Research and Treatment. 69(3). 2 indexed citations

17.

Pegram, M. & DJ Slamon. (2000). Biological rationale for HER2/neu (c-erbB2) as a target for monoclonal antibody therapy.. PubMed. 27(5 Suppl 9). 13–9. 123 indexed citations

18.

Pauletti, Giovanni M., et al.. (1996). Detection and quantitation of HER-2/neu gene amplification in human breast cancer archival material using fluorescence in situ hybridization.. PubMed. 13(1). 63–72. 458 indexed citations

19.

Press, Michael F., Giun‐Yi Hung, William Godolphin, & DJ Slamon. (1994). Sensitivity of HER-2/neu antibodies in archival tissue samples: potential source of error in immunohistochemical studies of oncogene expression.. PubMed. 54(10). 2771–7. 414 indexed citations

20.

Bacus, S S, et al.. (1990). HER-2/neu oncogene expression and DNA ploidy analysis in breast cancer.. PubMed. 114(2). 164–9. 64 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact